These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 16908160)

  • 1. FXR, a multipurpose nuclear receptor.
    Lee FY; Lee H; Hubbert ML; Edwards PA; Zhang Y
    Trends Biochem Sci; 2006 Oct; 31(10):572-80. PubMed ID: 16908160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis.
    Cariou B
    Diabetes Metab; 2008 Dec; 34(6 Pt 2):685-91. PubMed ID: 19195631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FXR: a metabolic regulator and cell protector.
    Wang YD; Chen WD; Moore DD; Huang W
    Cell Res; 2008 Nov; 18(11):1087-95. PubMed ID: 18825165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism.
    Claudel T; Staels B; Kuipers F
    Arterioscler Thromb Vasc Biol; 2005 Oct; 25(10):2020-30. PubMed ID: 16037564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of bile acids and bile acid receptors in metabolic regulation.
    Lefebvre P; Cariou B; Lien F; Kuipers F; Staels B
    Physiol Rev; 2009 Jan; 89(1):147-91. PubMed ID: 19126757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of FXR in disorders of bile acid homeostasis.
    Eloranta JJ; Kullak-Ublick GA
    Physiology (Bethesda); 2008 Oct; 23():286-95. PubMed ID: 18927204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential regulatory role of the farnesoid X receptor in the metabolic syndrome.
    Duran-Sandoval D; Cariou B; Fruchart JC; Staels B
    Biochimie; 2005 Jan; 87(1):93-8. PubMed ID: 15733743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor.
    Yang F; Huang X; Yi T; Yen Y; Moore DD; Huang W
    Cancer Res; 2007 Feb; 67(3):863-7. PubMed ID: 17283114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia downregulates farnesoid X receptor via a hypoxia-inducible factor-independent but p38 mitogen-activated protein kinase-dependent pathway.
    Fujino T; Murakami K; Ozawa I; Minegishi Y; Kashimura R; Akita T; Saitou S; Atsumi T; Sato T; Ando K; Hara S; Kikugawa K; Hayakawa M
    FEBS J; 2009 Mar; 276(5):1319-32. PubMed ID: 19187229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The farnesoid X receptor induces very low density lipoprotein receptor gene expression.
    Sirvent A; Claudel T; Martin G; Brozek J; Kosykh V; Darteil R; Hum DW; Fruchart JC; Staels B
    FEBS Lett; 2004 May; 566(1-3):173-7. PubMed ID: 15147890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy.
    Jiang T; Wang XX; Scherzer P; Wilson P; Tallman J; Takahashi H; Li J; Iwahashi M; Sutherland E; Arend L; Levi M
    Diabetes; 2007 Oct; 56(10):2485-93. PubMed ID: 17660268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear bile acid receptor FXR as pharmacological target: are we there yet?
    Modica S; Moschetta A
    FEBS Lett; 2006 Oct; 580(23):5492-9. PubMed ID: 16904670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression.
    Marzolini C; Tirona RG; Gervasini G; Poonkuzhali B; Assem M; Lee W; Leake BF; Schuetz JD; Schuetz EG; Kim RB
    Mol Endocrinol; 2007 Aug; 21(8):1769-80. PubMed ID: 17519356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Farnesoid X receptor(FXR)].
    Fujii H
    Nihon Rinsho; 2001 Feb; 59 Suppl 2():309-12. PubMed ID: 11351595
    [No Abstract]   [Full Text] [Related]  

  • 15. Knockdown of ATP8B1 expression leads to specific downregulation of the bile acid sensor FXR in HepG2 cells: effect of the FXR agonist GW4064.
    Martínez-Fernández P; Hierro L; Jara P; Alvarez L
    Am J Physiol Gastrointest Liver Physiol; 2009 May; 296(5):G1119-29. PubMed ID: 19228886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes.
    Landrier JF; Eloranta JJ; Vavricka SR; Kullak-Ublick GA
    Am J Physiol Gastrointest Liver Physiol; 2006 Mar; 290(3):G476-85. PubMed ID: 16269519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of interleukin-6-induced C-reactive protein expression by FXR agonists.
    Zhang S; Liu Q; Wang J; Harnish DC
    Biochem Biophys Res Commun; 2009 Feb; 379(2):476-9. PubMed ID: 19118524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting farnesoid X receptor for liver and metabolic disorders.
    Fiorucci S; Rizzo G; Donini A; Distrutti E; Santucci L
    Trends Mol Med; 2007 Jul; 13(7):298-309. PubMed ID: 17588816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries.
    Nicolaou KC; Evans RM; Roecker AJ; Hughes R; Downes M; Pfefferkorn JA
    Org Biomol Chem; 2003 Mar; 1(6):908-20. PubMed ID: 12929628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders.
    Fiorucci S; Mencarelli A; Palladino G; Cipriani S
    Trends Pharmacol Sci; 2009 Nov; 30(11):570-80. PubMed ID: 19758712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.